| Technical Description |
This technology is exploring a new use for the NTUP413 in Alzheimer＇s disease, which has been shown to be a potential therapeutic agent for neurodegenerative diseases. |
| Scientific Breakthrough |
NTUP413 is a high selective HDAC6 inhibitorwell tolerated without cardiac toxicity. It decreases the levels of phosphor-tau/aggregation of tau,reduces neuronal apoptosis. NTUP413 can ameliorate learningmemory impairment in animal models. Oral administration NTUP413 can cross the blood-brain barrier. It shows that NTUP413 has the potential to develop as an AD therapeutic drug. |
| Industrial Applicability |
NTUP413 has potent HDAC6 inhibitory activityhigh selectivity for HDAC6, which can reduce side effects. Oral administration NTUP413 can penetrate blood-brain barrier it can reduce tau phosphorylation/aggregationsignificantly ameliorate learningmemory impairment by in vitroin vivo models. It shows that NTUP413 has the potential to further develop as an AD therapeutic drug. |
